ANTIMICROBIAL RESISTANCE AND FORMATION OF BIOFILM IN CLINICS ISOLATES CAUSERS OF INFECTIONS RELATED TO HEALTH CARE


ANTIMICROBIAL RESISTANCE AND FORMATION OF BIOFILM IN CLINICS ISOLATES CAUSERS OF INFECTIONS RELATED TO HEALTH CARE


Francisco Henrique da Silva, Sivoneide Maria da Silva, Bárbara de Azevedo Ramos, Maria Betânia Melo de Oliveira, Maria Tereza dos Santos Correia, Márcia Vanusa da Silva

Biochemistry Department, Federal University of Pernambuco, Recife, Pernambuco, Brazil


American Journal of Biotechnology and Bioinformatics

Healthcare-related infections (HAI) represent a great risk to their victims and are an increasing cost to the clinical and therapeutic setting. The fast increase in microbial resistance to antibiotics in the hospital environment decreases drug effectiveness, increases length of stay, and increases the cost of treatment. Besides that, it may result in premature death as a direct consequence of unsafe health practices, according to the World Health Organization. In this context, the present study aimed to evaluate microbial resistance and biofilm formation in isolates of clinical interest. The methodology used was based on the analysis and identification of clinical isolates of Enterococcus faecalis, Enterococcus faecium, Proteus mirabilis and Providencia stuartii, performed by the Vitek® 2 Compact automated system (bioMérieux) and confirmed by obtaining mass spectrum in MALDI-TOF apparatus. Autoflex III Mass Spectrometer which were compared with MALDI Biotyper version 3.1 database. Microbial resistance was evaluated by Minimum Inhibitory Concentration (MIC) and biofilm formation of these isolates by violet crystal method, Congo Red Agar and optical microscopy. As results, it was observed that all isolates tested were compatible with identification by MALDI-TOF. In addition, of all isolates tested, 83.3% had higher resistance to the antibiotic Ampicillin (AMP) and 58.3% showed resistance to Ciprofloxacin (CIP), ranging from Resistant Multidrug (MDR) to Extensively Drug Resistant (XDR), by various other antibiotics. All microorganisms presented biofilm formation ranging from moderate to strong, in which the strong ones represented 66.6% of isolates. It was observed that the identification of pertinent characteristics to microorganism might provide an effective therapy focused in reducing the infectious diseases related to HAI.


Keywords:Bacteria. MALDI-TOF. Therapy.

Free Full-text PDF


How to cite this article:
Francisco Henrique da Silva, Sivoneide Maria da Silva, Bárbara de Azevedo Ramos, Maria Betânia Melo de Oliveira, Maria Tereza dos Santos Correia, Márcia Vanusa da Silva. ANTIMICROBIAL RESISTANCE AND FORMATION OF BIOFILM IN CLINICS ISOLATES CAUSERS OF INFECTIONS RELATED TO HEALTH CARE. American Journal of Biotechnology and Bioinformatics, 2020; 3:8. DOI: 10.28933/ajobb-2020-03-1505


References:

1. WORLD HEALTH ORGANIZATION. The top 10 causes of death. In: The top 10 causes of death. [S. l.], 24 maio 2018. Disponível em: https://www.who.int/en/news- room/fact-sheets/detail/the-top-10-causes-of-death. Acesso em: 21 abr. 2019.
2. BODE, L. G., KLUYTMANS, J. A., WERTHEIM, H. F., BOGAERS, D., VANDENBROUCKE-GRAULS, C. M., ROOSENDAAL, R., van BELKUM, A. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. New England Journal of Medicine, 2010; 362(1), 9-17.
3. ALLEGRANZI, B., NEJAD, S. B., COMBESCURE, C., GRAAFMANS, W., ATTAR, H., DONALDSON, L., PITTET, D. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. The Lancet, 377(9761), 2011; 228-241.
4. LOUREIRO, R. J., ROQUE, F., RODRIGUES, A., T.HERDEIRO, M.T., RAMALHEIRA, E. O uso de antibióticos e as resistências bacterianas: breves notas sobre a sua evolução. Revista Portuguesa de Saúde Pública/Portuguese Journal of Public Health, 2016; 34(1).
5. Resolução RDC/ANVISA nº 48, de 02-06-2000.
6. SORIANO, F.N. Antibióticos frente a grampositivos: linezolid, tigeciclina, daptomicina, dalbavancina, telavancina, ceftobiprole. Enfermedades Infecciosas y Microbiología Clínica, 2008;26, 13-20.
7. DSOUZA, R. et al. Detecção In vivo de biofilmes de tubo endotraqueal em pacientes de terapia intensiva intubados que usam ótica cateter-baseada tomografia de coerência. J. Biophotonics. 2019.
8. BUSSCHER, H. J., van der MEI, H. C., SUBBIAHDOSS, G., JUTTE, P. C., VAN DEN DUNGEN, J. J., ZAAT, S. A., GRAINGER, D. W. Biomaterial-associated infection: locating the finish line in the race for the surface. Science translational medicine, 2012; 4(153), 153rv10-153rv10.
9. CLSI. Performance standards for antimicrobialsusceptibilitytesting. 28th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards institute, 2018.
10. FREEMAN, D. J., FALKINER, F. R., KEANE, C. T. New method for detecting slime production by coagulase negative staphylococci. Journal of clinical pathology, 1989; 42(8), 872-874.
11. STEPANOVIĆ, S., VUKOVIĆ, D., HOLA, V., BONAVENTURA, G. D., DJUKIĆ, S., ĆIRKOVIĆ, I., RUZICKA, F. Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. Apmis, 2007; 115(8), 891-899.
12. YANAGIDA, M., MIURA, Y., YAGASAKI, K., TAOKA, M., ISOBE, T., TAKAHASHI, N. Matrix assisted laser desorption/ionization‐time of flight‐mass spectrometry analysis of proteins detected by anti‐phosphotyrosine antibody on two‐dimensional‐gels of fibrolast cell lysates after tumor necrosis factor‐α stimulation. ELECTROPHORESIS: An International Journal, 2000;. 21(9), 1890-1898..
13. MAGIORAKOS, A. P., SRINIVASAN, A., CAREY, R. B., CARMELI, Y., FALAGAS, M. E., GISKE, C. G., PATERSON, D. L. Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection, 2012; 18(3), 268-281.
14. SILVA, A. D., WERNECK, L., HENRIQUES, C. T. Dinâmica da circulação de bactérias multirresistentes em unidades de terapia intensiva pediátrica do Rio de Janeiro. Revista de Epidemiologia e Controle de Infecção, 2012; 2(2), 41-45.
15. DE MACÊDO, J.A.B. Biofilmes bacterianos, uma preocupação da indústria de farmacêutica. Revista Fármacos & Medicamentos, 2000; 2(7), 19-24.
16. DA SILVA TRENTIN, D., GIORDANI, R. B., MACEDO, A. J. Biofilmes bacterianos patogênicos: aspectos gerais, importância clínica e estratégias de combate. Revista Liberato, 2013; 14(22), 213-236.
17. OLIVEIRA D.K, CARDOSO AM. Biofilmes microbianos: um desafio para a saúde.